Somite

About:

Somite is leveraging data and AI to introduce novel cell replacement therapies.

Top Investors: Darkmode Ventures, Astellas Venture Management, Trust Ventures, Lerer Hippeau, Next Coast Ventures

Description:

Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023, Somite.ai has raised over $10m to date.

Total Funding Amount:

$10.3M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2023-10-19

Contact Email:

hello(AT)somite.ai

Founders:

Allon Klein, Cliff Tabin, Jay Shendure, Jonathan Rosenfeld, Micha Y. Breakstone, Olivier Pourquie

Number of Employees:

11-50

Last Funding Date:

2024-04-11

IPO Status:

Private

Industries:

Biotechnology

Artificial Intelligence (AI)